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Discovery of Biomarker panels for 
Neural Dysfunction in Inborn errors 
of Amino Acid Metabolism
Alba-Aina Castells1,2, Daniela Gueraldi1, Rafel Balada2, Alba tristán-Noguero1, 
elisenda Cortès-saladelafont1, Federico Ramos1, Silvia Meavilla1, Mariela De Los santos1, 
Camila Garcia-Volpe1, Roser Colomé1, Maria Luz Couce3, Cristina sierra1, Aida Ormazábal1, 
Marta Batllori1, Rafael Artuch  1, Judith Armstrong1, Soledad Alcántara2 & Àngels Garcia-
Cazorla  1
patients with inborn errors of amino acid metabolism frequently show neuropsychiatric symptoms 
despite accurate metabolic control. this study aimed to gain insight into the underlying mechanisms 
of neural dysfunction. Here we analyzed the expression of brain-derived neurotrophic factor (BDNF) 
and 10 genes required for correct brain functioning in plasma and blood of patients with Urea Cycle 
Disorders (UCD), Maple Syrup Urine Disease (MSUD) and controls. Receiver-operating characteristic 
(ROC) analysis was used to evaluate sensitivity and specificity of potential biomarkers. CACNA2D2 
(α2δ2 subunit of voltage-gated calcium channels) and MECP2 (methyl-CpG binding protein 2) mRNA 
and protein showed an excellent neural function biomarker signature (AUC ≥ 0,925) for recognition 
of MSUD. THBS3 (thrombospondin 3) mRNA and AABA gave a very good biomarker signature (AUC 
0,911) for executive-attention deficits. THBS3, LIN28A mRNA, and alanine showed a perfect biomarker 
signature (AUC 1) for behavioral and mood disorders. Finally, a panel of BDNF protein and at least two 
large neural AAs showed a perfect biomarker signature (AUC 1) for recognition of psychomotor delay, 
pointing to excessive protein restriction as central causative of psychomotor delay. To conclude, our 
study has identified promising biomarker panels for neural function evaluation, providing a base for 
future studies with larger samples.
Although inborn errors of amino acid metabolism (IEM) are treatable disorders, long-term cognitive and behav-
ioral problems are almost constant in patients despite strict dietary management and other treatment approaches. 
Factors underlying brain dysfunction are not fully understood.
Urea cycle disorders (UCDs, OMIM #311250) are IEM characterized by recurrent hyperammonemic epi-
sodes, due to dysfunctions in any of the urea cycle pathway enzymes, a detoxification system that converts ammo-
nia into urea. In the brain, astrocytes are responsible for detoxifying ammonia through glutamine synthetase 
(GS) and the amidation of glutamate to glutamine1,2. Severe enzyme defects usually manifest symptoms during 
the first days of life, while symptoms of partial defects tend to appear later in life. Hyperammonemia can damage 
cerebral tissue by altering cerebral energy metabolism, glutamine/glutamate levels, neurotransmission, and signal 
transduction of pathways related to neuronal survival and plasticity3,4. Neurocognitive dysfunctions and behav-
ioral impairment represent common long-term outcomes that are likely to reflect chronic ammonia/glutamine 
toxicity5,6.
Maple syrup urine disease (MSUD; OMIM #248600) is caused by the deficiency of branched-chain α-keto 
acid dehydrogenase (BCKD) complex activity, a key enzyme for the amino acid catabolism, leading to increased 
levels of branched-chain amino acids (BCAAs) and their corresponding α-ketoacids7. The BCKD complex is 
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composed of three catalytic components: E1, E2 and E3 and two regulatory enzymes, the BCKD kinase (BCKDK) 
and BCKD phosphatase (PP2Cm)8. Mutations in BCKDK (OMIM #614923) are associated with decreased levels 
of BCAAs, epilepsy, intellectual disability and autism9.
Patients with the most severe form of MSUD develop metabolic decompensation and encephalopathy within 
the first weeks of life and die if untreated7,10,11. Therapy is based on strict dietary management with low BCAAs 
(mainly leucine) content and/or liver transplantation12,13. Despite treatment, several studies have described small 
reductions in the intelligence quotient and increased rate of neuropsychiatric conditions, mainly attention deficit 
hyperactivity disorder (ADHD), depression and anxiety14–18. Neurotoxicity of BCAAs and their α-ketoacids, 
mainly leucine, might underlie neuropsychiatric disorders, as leucine plasma concentrations are closely correlated 
with acute symptoms17. Due to blood-brain barrier (BBB) amino acid transporter saturation, increased BCAAs 
and α-ketoacids in the brain, are concomitant with deficiency of essential amino acids, causing brain-specific 
deficits in protein synthesis, neurotransmitter depletion and inhibition of mitochondrial enzymes8,19.
Early detection and treatment is the gold standard to avoid long-term disabilities in IEM patients. Therefore, 
there is a need to find new biomarkers of neural function for the identification and management of those children 
that, despite metabolic management, are at risk to develop neurologic, cognitive and behavioral problems.
One currently accepted biomarker candidate for brain functioning is brain-derived neurotrophic fac-
tor (BDNF), as BDNF signaling is involved in brain development, synaptic function and plasticity20. 
Activity-dependent regulation of BDNF expression is in part mediated by transcription factor methyl-CpG bind-
ing protein 2 (MeCP2), and altered levels of MeCP2, BDNF or their downstream signaling are widely implicated 
in neuropsychiatric diseases and mood disorders21,22. Altered BDNF levels in plasma have been recently described 
in MSUD patients and the hippocampus of hyperammonemic rats23,24. BDNF is also involved in glucose and 
energy homeostasis through control of energy intake and expenditure25, in part by regulation of miRNA and 
protein synthesis through LIN28A RNA-binding protein26,27. Additional candidate biomarkers are CACNA2D1-2 
genes, which codify for α2δ1-2 regulatory subunits of the voltage-gated calcium channels (VGCCs)28. Aside from 
its modulatory channel function, α2δ1-2 are essential for the formation and stabilization of new synapses by 
binding to oligomeric extracellular matrix glycoproteins thrombospondins (TSPs), which are codified by THBS 
genes29. L-leucine and L-isoleucine are also well-known ligands of α2δ1-2 subunits30 and have been postulated as 
necessary for their correct function31,32.
Therefore, to gain insight into the molecular mechanisms underlying neurological deficits in IEM patients, we 
analyzed in peripheral whole blood the mRNA expression of a group of genes involved in brain development and 
synaptic function (ADORA2A, CACNA2D2, FMR1, IRAK1, LIN28A, PTEN, MECP2 E1/E2, THBS1, THBS3) in 
a cohort patients affected by UCD, MSUD and BCKDK deficiency. Gene expression in blood was correlated with 
AAs profile, BDNF protein levels in plasma, and neuropsychological symptoms, in an attempt to identify specific 
molecular pathways altered in each disorder, as well as common mechanisms underlying the pathophysiology of 
the neurological impairment present in different IEMs.
Results
Clinical information of patients. Table 1 shows a summary of clinical data and Table 2 shows treatment 
details and historical biochemical parameters of IEM patients included in this study.
UCD patients (7 males and 12 females) include ornithine transcarbamylase deficiency (OTC deficiency) 
(14), citrullinemia type I (CTLN1) (3), hyperornithinemia-hyperammonemia-homocitrullinuria syndrome, 
(HHH syndrome) (1) and argininosuccinate lyase deficiency (ASL deficiency) (1), and five of them (26%) were 
asymptomatic. All UCD patients were treated with L-Arginine +/− L-Citrulline and all but two followed a 
protein-restricted diet (0.5–1,3 g/Kg/day). Asymptomatic patients showed mean glutamine levels <800 µmol/L; 
while half of symptomatic patients showed mean glutamine levels ≥800 µmol/L. Eight symptomatic patients 
(42%) were treated with ammonia scavengers, all with sodium phenylbutyrate (NaPB) and one also with sodium 
benzoate. Patients without scavengers were those with normal ammonia and amino acids in the follow-up 
metabolic controls. MSUD patients (3 males and 6 females) include mutations in DBT (2) and BCKDHB (6), 
one of them asymptomatic. We also included a patient with a genetic diagnose of BCKDK deficiency. MSUD 
patients followed a low BCAA diet while BCKDK deficiency patient received a high protein diet supplemented 
with BCAAs. Despite low BCAA diet, mean leucine levels ≥200 µmol/L (normal range in young patients <200 
µmol/L) were observed in 78% of MSUD patients.
From the 29 IEM patients in our cohort, 21 symptomatic patients had a neuropsychological evaluation to 
detect abnormal executive functions and attention deficits (15 patients) cognitive disabilities (7 patients) and 
other behavioral disorders (7 patients). Three patients of those who fulfilled ADHD criteria and had poor aca-
demic results were treated with psychostimulants (methylphenidate). Neuropsychological evaluation was not 
performed in healthy control subjects (n = 27) and in asymptomatic patients that achieved successfully both 
academic and personal life events (n = 8).
Analysis of metabolite levels. The 21 principal amino acids and 4 amino acid related-compounds 
were measured in all plasma samples by ion-exchange chromatography with nynhydrin detection derivatives. 
Ammonia levels were measured only in OTC patients. Average values for each condition are shown in Table 3.
Despite metabolic management, several mean AAs values were out of normal range both in UCD and MSUD 
groups (Table 3). The mean ammonia level in the UCD group was in the normal range but nitrogen-rich AAs 
glutamine (p > 0.0001) and asparagine (p = 0.014) were significantly increased in UCD patients with respect to 
controls; and as were with glycine (p = 0.014), methionine (p > 0.0001) and histidine (p = 0.000). As expected, 
citrulline was only increased in patients with ASS deficiency (p = 0.04). When segregating UCD patients by treat-
ment, patients treated with ammonia scavengers showed specific downregulations of phenylalanine (p = 0.045) 
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Patient Sex Disorder Defect
Age at
onset Symptoms at onset
Age at 
blood 
analysis
NPSY tests
(evaluative 
age)
Intellectual 
Disability
Psychomotor 
delay
Executive function/
attention deficits
Other Behavioral 
symptoms
1 M UCD OTC (^) Asymptomatic 16 y NO (*) NO NO NO NO
2 M UCD OTC 9 d Lethargy, failure to thrive 10 y
YES
(7, 11 y)
NO
(IQ: 120) NO ADHD Autistic traits
3 M UCD OTC 8 y Seizures, learning difficulties 19 y
YES
(13 y)
NO
(IQ: 88) NO
Verbal, visual and 
working memory 
deficits
Mood disorder, depression
4 F UCD OTC — Asymptomatic 36 y NO (*) NO NO NO NO
5 M UCD HHH 20 m
Mild psychomotor 
delay, lower limb 
pyramidal signs
12 y YES(7 y)
YES
(IQ: 76) YES
ADHD,
inhibition and literacy 
affected
NO
6 M UCD ASL 3 y Language delay 13 y YES(7 y)
YES
(IQ: 54) YES
Verbal, attention and 
working memory 
deficits
Language and verbal 
comprehension difficulties
7 M UCD OTC 4 y Cyclic vomitinghyporeactivity, seizures 13 y
YES
(11 y)
NO
(IQ: 106) NO
ADHD, working 
memory deficits NO
8 F UCD OTC 6 y Ataxia confusion, vomit, lethargy 22 y NO (*) NO NO NO NO
9 F UCD OTC 2 y Fever, food refusal, irritability 5 y
YES
(6 y) NO (IQ:104) NO
Attention and working 
memory deficits NO
10 F UCD OTC 14 y Coma 19 y YES(16 y)
YES
(IQ: 70) YES
Attention and working 
memory deficits NO
11 F UCD OTC (^) Asymptomatic 10 y NO (*) NO NO NO NO
12 F UCD OTC (+) Asymptomatic 42 y NO (*) NO NO NO NO
13 M UCD ASS 8 y Behavior disorder, ADHD 16 y
YES
(17 y)
YES
(IQ: 52) YES
ADHD, working 
memory deficits Irritability, aggressiveness
14 F UCD OTC 8 m Vomit, food refusal, hyporeactivity 10 y NO NO NO — NO
15 F UCD OTC 3 y Hyporeactivity 6 y NO NO YES — NO
16 F UCD ASS 2 d Lethargy 9 y YES(12 y) NO YES ADHD Autistic traits
17 F UCD OTC 3 y Lethargy, seizures, coma 9 y
YES
(7 y)
YES
(IQ: 50) YES
Attention and working 
memory deficits
Disruptive and self-harm 
behavior
18 F UCD OTC 2 y Coma 12 y YES(10 y)
NO
(IQ: 88) NO NO NO
19 F UCD ASS NS Asymptomatic 3 y NO (*) NO(IQ: 107) NO NO NO
20 M MSUD DBT (E2) 9 d Poor feeding,lethargy 1 y YES NO (IQ:88) NO NO NO
21 F MSUD BCKDHB(Ib) 10 d Poor feeding, lethargy 19 y YES YES(IQ 70–85) NO NO NO
22 F MSUD BCKDHB(Ib) 9 d Poor feeding,lethargy 2 y YES
NO
(IQ ≥ 85) NO Attention deficits NO
23 F MSUD DBT (E2) 11 d Poor feeding, lethargy 3 m YES(3 y)
NO
(IQ: 93) NO NO NO
24 M MSUD BCKDHB(Ib) 7 d Poor feeding, coma, sweet odor smelling 13 y
YES
(8 y)
NO
(IQ: 89) NO Attention deficits NO
25 F MSUD BCKDHB(Ib) 7 d
Poor feeding,
lethargy, sweet odor 
smelling
4 m YES(6 y) NO (IQ:104) NO NO NO
26 M MSUD BCKDHB(Ib) 7 d Poor feeding,coma 19 m
YES
(1 y) NO (IQ:90) NO
Attention and working 
memory deficits NO
27 F MSUD BCKDHB(Ib) NS Asymptomatic 28 d NO (*)(4 y) NO (IQ:108) NO NO NO
28 F MSUD BCKDHB(Ib) 10 d Poor Feeding,lethargy 6 y YES
NO
(IQ ≥ 85) NO Attention deficits NO
29 M BCKDKDeficiency BCKDK 1 m
Psychomotor delay, 
gastrointestinal 
symptoms, moderate 
anorexia
6 y YES YES (IQ < 35) YES YES
Autism disorder, aggressive 
disorder
Table 1. Summary of clinical characteristics, disease onset and outcome of IEM patients. ADHD: 
attention deficit hyperactivity; ASL Argininosuccinate Lyase; ASS: Argininosuccinate synthetase, 
HHH: Hyperornithinemia-Hyperammonemia-Homocitrullinuria, IQ: Intelligence Quotient, IQNPSY: 
Neuropsychological tests not done but asymptomatic and normal academic and social achievements; MSUD: 
Maple Syrup Urine Disease, NS: Newborn Screening; OTC: Ornithine transcarbamylase, UCD: Urea Cycle 
Disorders, (*) M: male, F: female, d: days; m: months; y: years; - unknown; n.a. not applicable. (^): diagnosed 
because of an affected sibling. (+): diagnosed because of an affected son.
4Scientific RepoRts |          (2019) 9:9128  | https://doi.org/10.1038/s41598-019-45674-2
www.nature.com/scientificreportswww.nature.com/scientificreports/
and BCAAs (Val p = 0.013; Leu p = 0.003; Ile, p = 0.015) with respect to untreated UCD patients and phenylala-
nine (p = 0.032) and valine (p = 0.041) also with respect to controls.
BCAAs levels were high in most MSUD patients with leucine (p = 0.01) and isoleucine (p = 0.000) over 
the control group. glycine (p = 0.000), taurine (p = 0.000), serine (p = 0.004), threonine (p = 0.002), glutamate 
(p = 0.024), asparagine (p = 0.019), histidine (p = 0.017) and ornithine (p = 0.026) were also significantly ele-
vated in MSUD group with respect to controls. The only BCKDK deficiency patient analyzed showed normal 
BCAAs, a marked decrease in α-Aminobutyric acid (AABA) and levels above the normal range in other twelve 
AAs (Table 3).
mRNA and protein expression analysis. To ensure the reliability of RT-PCR analysis we set strict sam-
ple exclusion criteria (see patients and methods) and as a result, 27 controls, 16 UCD, 7 MSUD, and 1 BCKDK 
deficiency patients were included in mRNA and further analysis. In addition, outliers were also excluded from 
the analysis.
A summary of significant differences in mRNA RT-PCR analysis is shown in Table 4. MSUD and UCD groups 
exhibit significant differences in mRNA gene expression profiles with respect to controls and between them. All 
genes analyzed in the BCKDK deficiency patient were in the control range. In MSUD patients, CACNA2D2, and 
MECP2 E1 and E2 isoforms mRNAs were significantly downregulated (p = 0.007; p = 0.027; p = 0.001 respec-
tively), while THBS1 mRNA was upregulated (p = 0.047) with respect to controls. In UCD patients, THBS1 and 
LIN28A mRNA were upregulated with respect to controls (p = 0.031; p = 0.023 respectively). No differences 
between groups were found for FMR1, IRAK1, PTEN, and THBS3.
When UCD patients were segregated by ammonia scavenger treatment, ADORA2A mRNA was significantly 
increased in those treated with scavengers (n = 8) with respect to control group (p = 0.042) and UCD untreated 
group (n = 8, p = 0.021). In addition, MECP2 E1 (p = 0.047) and THBS1 (p = 0.031), mRNA were significantly 
increased in those treated with scavengers with respect to control group, but not to untreated UCD patients. 
Taken together these results suggest that ammonia scavenger treatment might directly increase, THBS1, MECP2 
E1, and ADORA2A mRNA expression.
To evaluate the protein expression of the main potential gene biomarkers identified in this study, we per-
formed western blot analysis in purified leukocytes from the same blood samples. We found that protein levels 
of α2δ2 and MeCP2 in leukocytes from MSUD patients (n = 8) was significantly lower than in controls (n = 5) 
(p = 0.011, p = 0.048, respectively), corroborating our mRNA results in whole blood (Fig. 1d). Finally, BDNF 
protein was measured by ELISA in plasma from the same samples included in the mRNA analysis. BDNF levels 
were highly variable, even in controls, and although no statistically significant differences were found between 
groups, there was a tendency of lower levels of BDNF in UCD patients (p = 0.061).
spearman correlation between levels of candidate biomarkers and amino acids. We then inves-
tigated correlations among potential neural function biomarkers and relevant amino acids using Spearman coef-
ficient of pairwise comparison between samples (Fig. 2). Correlations were performed between each candidate 
biomarker for the overall population and relevant statistically significant correlations were identified from the 
correlation matrix heat map obtained. Spearman coefficient (ρ) of 1 or −1 represents perfect positive or negative 
correlation respectively.
We found a positive correlation between glutamine levels in plasma and mRNA levels in blood of THBS1 
(ρ = 0.342; p = 0.025) and THBS3 (ρ = 0.313; p = 0.041), which were also positively correlated between them 
(ρ = 0.449; p = 0.005). In addition, THBS1 mRNA positively correlated with LIN28A mRNA (ρ = 0.312; 
p = 0.047), and negatively with BDNF protein levels (ρ = −0.348; p = 0.019); while THBS3 mRNA positively cor-
related with mRNA levels of MECP2 e1 and e2 isoforms (ρ = 0.353/0.433; p = 0.032/0.007 respectively), PTEN 
(ρ = 0.450; p = 0.006) and FMR1 (ρ = 0.447; p = 0.033). We also found a significant strong negative correla-
tion between mean historical leucine levels and BCAAs receptor CACNA2D2 mRNA (ρ = −0.857; p = 0.014); 
and a significant positive correlation between mean historical leucine levels and taurine (ρ = 0.648; p = 0.043). 
Consistently, CACNA2D2 mRNA also had a significant negative correlation with taurine (ρ = −0.420; p = 0.006), 
isoleucine (ρ = −0.377; p = 0.015) and glutamate (ρ = −0.378; p = 0.015), three AAs that are significantly 
increased in MSUD patients.
Identification of UCD and MSUD gene biomarker signature. To validate the potential diagnostic 
and recognition effectiveness of neural function biomarker panels, ROC analysis was applied and the area under 
the ROC curve (AUC) was calculated for each candidate biomarker. AUC value varies from 0 to 1, where values 
0.8 > AUC < 0.9 and 0.9 > AUC < 1 reflect good and very good biomarker performance respectively.
We first tested sensibility and specificity of candidate biomarkers altered in MSUD or UCD patients with 
respect to control group, and a summary of relevant potential gene biomarkers is shown in Table 5 and Fig. 1. 
From BDNF and the 10 genes analyzed in this study only LIN28A (AUC = 0.712) and THBS1 (AUC = 0.707) 
exhibit fair biomarker accuracy for UCD. On the contrary, in the case of MSUD, good or very good biomarker 
performance was found for MECP2 (AUC E2 mRNA = 0.942, E1 mRNA = 0.802, MeCP2 protein = 0.857), 
CACNA2D2 (AUC CACNA2D2 mRNA = 0.865, α2δ2 protein = 0.925) and with less accuracy THBS1 (AUC 
mRNA = 0.791). Biomarker specificity and sensitivity are maximal when MECP2 E2 and CACNA2D2 mRNA are 
simultaneously considered (AUC mRNA = 1, protein = 0.95). Taking together, these results suggest that altered 
α2δ2 and MeCP2 signaling might be involved in the neural function deficits present in MSUD patients.
Identification of gene biomarker signature of neural function in IEM patients. We used the 
Kruskal Wallis test to identify significant correlations between candidate biomarkers and the presence of neu-
ropsychological symptoms. No significant correlations were found between individual candidate mRNA 
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biomarkers or BDNF and neuropsychological symptoms within MSUD or UCD patients, and the only BCKDK 
deficiency patient included in the study precludes this type of analysis.
To identify common traits for neuropsychological deficits in IEMs we then analyzed all patient samples as a 
whole. Low BDNF and threonine levels in plasma, a clinical indicator of protein restriction, have a statistically 
Patients Diagnosis Treatment
Historical data (µmol/L)
N° metabolic 
decompensations
Am (<50)
Gln 
(330–754) Leu (<200)
Mean Max Mean Max Mean Max
1 OTC L-arginine, L-citrullineProtein-restricted diet 0 25 38 585 734 — —
2 OTC NaPBMethylphenidate
L-arginine, L-citrulline
L-carnitine
Protein-restricted diet
4 53 290 865 1387 — —
3 OTC L-arginine, L-citrullineProtein-restricted diet 1 47 282 721 1766 — —
4 OTC
L-citrulline, L-arginine
L-carnitine
Protein-restricted diet
0 31 55 727 1029 — —
5 HHH Methylphenidate
L-arginine, L-citrulline
L-carnitine
Protein-restricted diet
0 61 220 683 1060 — —
6 ALS L-arginineProtein-restricted diet 0 28 45 505 667 — —
7 OTC Methylphenidate L-arginine, L-carnitineProtein-restricted diet 2 37 650 562 835 — —
8 OTC L-citrulline, L-carnitineProtein-restricted diet 1 45 247 855 1274 — —
9 OTC NaPB L-arginineProtein-restricted diet 2 59 180 1203 1792 — —
10 OTC NaPB L-arginine, L-citrullineProtein-restricted diet 2 30 485 800 1320 — —
11 OTC NaPB L-ArginineProtein-restricted diet 0 40 67 626 796 — —
12 OTC L-arginine, L-citrullineProtein-restricted diet 0 36 50 797 1085 — —
13 ASS NaPB L-arginine, L-carnitineProtein-restricted diet 0 34 44 804 1174 — —
14 OTC
Liver Transplantation: 
Tacrolimus, Magnogene, 
Methylprednisolon, 
Septrin, Usochol, 
L-citrulline
1 67 669 874 1664 — —
15 OTC NaPB L-citrullineProtein-restricted diet 1 51 216 723 889 — —
16 ASS Na-Benzoate NaPB L-carnitine, L-arginineProtein-restricted diet 6 67 419 760 1288 — —
17 OTC NaPB L-citrulline, L-carnitineProtein-restricted diet 1 — 550 — — — —
18 OTC L-citrulline, L-carnitineProtein-restricted diet 4 30 288 1000 1380 — —
19 ASS L-arginine 0 20 22 400 622 — —
20 MSUD Low BCAA diet 2 — — — 324 -
21 MSUD Low BCAA diet — — — — 414 1507
22 MSUD Low BCAA diet 5 — — — 278 2717
23 MSUD Low BCAA diet 1 — — — 302 1760
24 MSUD Low BCAA diet 5 — — — 239 1155
25 MSUD Low BCAA diet 1 — — — 211 1692
26 MSUD Low BCAA diet 1 — — — 162 968
27 MSUD Low BCAA diet 0 — — — 95 262
28 MSUD Low BCAA diet 5 — — — 378 3241
29 BCKDK High BCAA diet n.a. — — — 101 197
Table 2. Treatment and historical biochemical data records of IEM patients. Abbreviations: Am: ammonia, 
ASL Argininosuccinate Lyase, ASS: Argininosuccinate synthetase, Gln: glutamine, HHH: Hyperornithinemia-
Hyperammonemia-Homocitrullinuria, n.a. not applicable, Leu: leucine, MSUD: Maple Syrup Urine Disease, 
NaPB Sodium phenylbutyrate, OTC: Ornithine transcarbamylase, UCD: Urea Cycle Disorders.
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significant correlation with impaired psychomotor development (BDNF p = 0.035; Thr p = 0.009) (Fig. 3a). On 
the other hand, increased LIN28A mRNA expression in blood and increased levels of alanine and cysteine in 
plasma significantly correlated with the presence of other behavioral symptoms (LIN28A p = 0.032; Ala p = 0.025; 
Cys p = 0.027) (Fig. 3c). Nevertheless, we could not detect LIN28A protein expression in purified leukocytes 
samples.
We then calculated AUC coefficients and a summary of the relevant potential effectiveness of candidate 
neural function biomarkers is shown in Table 6. For psychomotor delay, the combination of BDNF in plasma 
(µmol/L)
Control 
(n = 27) MSUD (n = 9)
BCKDK 
(n = 1) UCD (n = 19) UCD w/sc.(n = 8)
UCD w/o sc. 
(n = 11)
Val 187.51 ± 34.18 201.42 ± 112,82 251.40 181.50 ± 69.15 138.61 ± 41.30*£ 219.62 ± 67.80
Leu 96.29 ± 19.95 233.49 ± 158.75** 115.20 101.04 ± 43.21 72.89 ± 20.96££ 126.06 ± 43.05
Ile 50.19 ± 9.82 165.61 ± 103.22*** 63.40 56.26 ± 25.01 41.78 ± 13.89£ 69.14 ± 26.19
Gly 194.83 ± 44.63 320.73 ± 104.39*** 262.30 245.21 ± 69.42* 245.03 ± 67.71 245.37 ± 75.02
Ala 305.92 ± 57.86 311.02 ± 134.13 492.00 365.24 ± 148.94 407.30 ± 179.26 327.86 ± 113.61
Ser 110.16 ± 24.56 146.30 ± 34.32** 169.80 116.05 ± 30.19 108.49 ± 21.24 122.77 ± 36.34
Pro 147.81 ± 39.78 208.28 ± 87.01 273.30 157.75 ± 43.21 151.69 ± 49.32 163.19 ± 39.19
Thr 111.58 ± 22.07 204.50 ± 92.04**## 189.10 100.32 ± 42.40 83.89 ± 34.41 114.92 ± 45.26
Cys 31.13 ± 5.81 29.31 ± 7.59 35.60 33.72 ± 7.72 30.59 ± 7.78 36.51 ± 6.91
Met 19.05 ± 3.46 22.94 ± 6.29 49.10 26.80 ± 7.66*** 26.86 ± 9.66 26.74 ± 5.97**
Phe 50.23 ± 9.05 61.60 ± 22.50 95.00 46.64 ± 11.98 39.25 ± 7.41*£ 53.14 ± 11.69
Tyr 57.55 ± 15.65 76.21 ± 32.77 140.40 55.33 ± 17.41 50.55 ± 19.88 59.58 ± 14.73
Trp 52.78 ± 11.66 69.26 ± 25.81 99.80 53.61 ± 19.15 45.65 ± 20.21 60.68 ± 16.02
Asp 5.39 ± 3.36 6.31 ± 2.30 4.30 4.86 ± 2.77 4.36 ± 1.95 5.30 ± 3.40
Glu 25.96 ± 20.88 39.16 ± 18.79* 22.20 28.36 ± 10.74 34.39 ± 8.73 23.00 ± 9.76
Gln 414.87 ± 50.12 478.48 ± 92.18# 579.00 666.14 ± 146.69*** 753.53 ± 138.38*** 588.46 ± 108.89**
Asn 52.78 ± 8.51 44.27 ± 15.94*## 98.80 64.64 ± 19.80* 58.66 ± 6.54 69.94 ± 26.06
Hys 71.27 ± 9.95 81.39 ± 10.83* 110.10 90.16 ± 20.03*** 84.83 ± 8.10* 94.90 ± 26.29*
Lys 142.68 ± 16.61 183.19 ± 46.93 281.00 143.41 ± 49.44 127.75 ± 26.96 157.33 ± 61.56
Arg 54.61 ± 13.84 67.67 ± 34.43 90.90 66.33 ± 27.41 65.50 ± 28.66 67.07 ± 27.99
Orn 64.11 ± 21.45 90.80 ± 31.68* 72.80 97.83 ± 90.00 75.81 ± 36.94 117.40 ± 118.70
Tau 47.82 ± 21.75 93.97 ± 38.38***## 39.10 42.57 ± 19.56 45.76 ± 27.97 39.73 ± 7.82
Cit 27.16 ± 7.62 28.28 ± 4.65 28.70 258.55 ± 657.39 514.23 ± 919.91 31.28 ± 19.42
Oh-Pro 12.73 ± 6.11 15.98 ± 6.92 16.50 15.48 ± 8.94 12.25 ± 4.35 18.34 ± 11.13
AABA 20.70 ± 6.09 20.64 ± 4.06 4.50 22.76 ± 11.15 19.29 ± 6.48 25.84 ± 13.75
Ammonia — — — 35.94 ± 22.38 45.33 ± 33.03 30.30 ± 11.61
Table 3. Summary of biochemical profile. Results are presented as mean ± standard deviation. *Show 
statistical differences with respect to control, #with respect to UCD and £with respect to UCD without ammonia 
scavengers and assessed by Kruskal Wallis test. */£/#P < 0.05, **/££/##p < 0.01, ***/£££/###p < 0.001. w/sc. with 
scavenger treatment, w/o sc. without scavenger treatment.
Control (n = 28) MSUD (n = 7)
BCKDK 
(n = 1) UCD (n = 16)
UCD w/sc. 
(n = 8)
UCD w/o sc. 
(n = 8)
RQ
ADORA2A 1.03 ± 0.24 1.13 ± 0.21 1.304 1.11 ± 0.35 1.30 ± 0.35*£ 0.93 ± 0.25
CACNA2D2 1.03 ± 0.34 0.55 ± 0.20**## 0.884 1.03 ± 0.22 1.08 ± 0.24 0.96 ± 0.19
FMR1 1.05 ± 035 0.99 ± 0.12 — 1.21 ± 0.21 1.18 ± 0.18 1.23 ± 0.25
IRAK1 1.02 ± 0.17 1.07 ± 0.17 1.218 1.10 ± 0.24 1.14 ± 0.24 1.06 ± 0.26
LIN28A 1.12 ± 0.72 0.65 ± 0.20## 0.831 2.42 ± 1.92* 1.82 ± 1.11 3.03 ± 2.42
MECP2 E1 1.00 ± 0.23 0.79 ± 0.17*# — 1.15 ± 0.28 1.23 ± 0.28* 1.04 ± 0.26
MECP2 E2 1.05 ± 0.14 0.79 ± 0.08***### 1.150 1.01 ± 0.18 0.99 ± 0.20 1.02 ± 0.16
PTEN 1.04 ± 0.31 0.98 ± 0.47 0.826 1.42 ± 0.61 1.24 ± 0.46 1.60 ± 0.72
THBS1 0.99 ± 0.56 1.73 ± 0.66* 0.713 1.54 ± 0.81* 1.80 ± 0.95* 1.29 ± 0.58
THBS3 1.00 ± 0.21 1.01 ± 0.06 1.140 1.14 ± 0.22 1.16 ± 0.23 1.11 ± 0.22
ng/mL BDNF 136.20 ± 88.54 122.68 ± 68.03 — 77.64 ± 61.46 93.22 ± 85.24 67.26 ± 42.01
Table 4. Gene and BDNF protein expression in peripheral blood. Data are shown as mean ± standard 
deviation. *Show statistical differences with respect to control, #with respect to UCD and £with respect to UCD 
without ammonia scavengers assessed by Kruskal Wallis test. */£/#P < 0.05. **/££/##p < 0.01. ***/£££/###p < 0.001. 
w/sc. with scavenger treatment. w/o sc. without scavenger treatment.
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and MECP2 E1 mRNA in whole blood exhibited very good biomarker accuracy (AUC = 0.909). However, accu-
racy improved when BDNF was combined with serine or threonine in plasma, reaching maximal accuracy 
(AUC = 1) when a third amino acid between leucine, isoleucine or citrulline was added (Fig. 3a). Unexpectedly, 
Figure 1. ROC curves of different neural function biomarker combinations for diagnosis between MSUD or 
UCD patients and healthy controls. (a) UCD; (b) MSUD mRNA; (c) MSUD protein; (d) Representative western 
blot and densitometric analysis showing significant differences for α2δ2 and MeCP2 in MSUD patients (n = 8) 
and controls (n = 5). *p < 0.05, Mann-Whitney U test.
Figure 2. Correlations matrix heat maps. Heat map of Spearman correlation between amino acids and 
potential gene biomarkers performed between each biomarker for the overall population analyzed. 1 is positive 
correlation. 0 no correlation and −1 is negative correlation. Statistically significant correlations (p < 0.05) are 
black boxed.
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although no significant differences were found in mRNA in whole blood or in protein expression in leukocytes 
(data not shown), THBS3 mRNA exhibited good biomarker performance for executive functions and attention 
deficits (AUC = 0.857). Biomarker performance increased when THBS3 was combined with AABA in plasma 
(AUC = 0.911) (Fig. 3b). Finally, the combination of THBS3 and LIN28A mRNA exhibited good biomarker per-
formance to detect other behavioral symptoms (AUC = 0.870) in IEM patients, reaching maximal accuracy when 
was added alanine levels in plasma (AUC = 1) (Fig. 3c).
Taking together, these data point to excessive protein restriction and reduced BDNF levels as hallmarks of psy-
chomotor delay in IEM patients, and point to THBS3 signaling as involved in executive and attention functions, 
and THBS3 with LIN28A in behavior control.
Discussion
UCD and MSUD are intoxication-type IEM while BCKDK deficiency results in BCAAs deficits, and despite 
correct metabolic management, affected patients frequently suffer psychomotor delay, cognitive, behavioral and 
psychiatric conditions. To date, early detection and rigorous medical follow-up is the gold standard to minimize 
neuropsychiatric sequelae19,33,34.
Several studies have assessed amino acid expression in plasma samples of UCD and MSUD patients. However, 
no biomarkers directly correlated with the neuropsychological features, and the molecular mechanisms involved 
are still poorly understood35,36. To our knowledge, this is the first study where the mRNA expression of genes 
involved in brain development and synaptic function were assessed in blood from IEM patients and correlated 
with BDNF and metabolite profiles in plasma.
The main limitation of this study is the reduced sample size (UCD n = 19, MSUD n = 9, and BCKDK defi-
ciency n = 1), as IEMs are rare disorders. The use of blood is also challenging, as biomarker levels in blood can 
be highly variable and do not directly correlate with levels in brain, especially in diseases with preserved BBB 
integrity as IEMs. Even with these limitations, we found specific biomarker signatures for MSUD patients and 
neuropsychiatric dysfunctions in IEMs patients, that pointed to CACNA2D2, THBS1,3, MECP2, and LIN28A as 
new potential phenotype modifiers, after further investigation and verification with larger samples.
The first conclusion of this study is that despite metabolic management, most of symptomatic UCD and 
MSUD patients in our cohort still had glutamine and leucine/isoleucine respectively in the upper limits or above 
the normal range, and general AAs plasma profile in patients significantly differed from healthy controls.
In the case of MSUD, our data corroborate previous studies conducted in Brazilian and Filipino patients 
affected with MSUD which reported altered biochemical profile but no correlation between biochemical markers 
in serum and neuropsychological features23,35. However, we did not find a significant reduction in plasma BDNF 
levels as reported in Brazilian patients23, which might reflect different metabolic management and nutritional 
status in the two MSUD cohorts. In our cohort, none of the MSUD patients reported psychomotor delay while it 
was highly prevalent in the Brazilian cohort (40%).
BDNF levels are highly variable and directly related to food intake and energy metabolism37 and a reduction 
in BDNF expression was found in brains of rat offspring after maternal low-protein diet38. In this sense, 42% of 
our IEM cohort presented some degree of psychomotor delay, mostly corresponding to UCD patients treated with 
Biomarker Panel
MSUD UCD
AUC
Desv 
error p value Trend AUC
Desv 
error p value Trend
Leu 0.786 0.111 0.011 ↑
Ile 0.901 0.082 <0.001 ↑
Tau 0.889 0.055 0.001 ↑
Glu 0.753 0.085 0.025 ↑
Gly 0.909 0.048 <0.001 ↑
Gln 0.972 0.027 <0.001 ↑
CACNA2D2 0.865 0.720 0.007 ↓
LIN28A 0.716 0.092 0.133 ↓ 0.712 0.088 0.023 ↑
MECP2 E1 0.802 0.090 0.027 ↓
MECP2 E2 0.942 0.045 0.001 ↓
THBS1 0.791 0.089 0.046 ↑ 0.707 0.083 0.031 ↑
MECP2 E1 + MECP2 
E2 0.954 0.042 0.001
MECP2 
E2 + CACNA2D2 1.000 <0.001 <0.001
THBS1 + CACNA2D2 0.953 0.044 0.003
THBS1 + LIN28A 0.731 0.090 0.018
α2δ2 0.925 0.081 0.013 ↓
MeCP2 0.857 0.112 0.042 ↓
α2δ2 + MeCP2 0.95 0.06 0.008
Table 5. Area under the curves (AUC) of the biomarker combinations for MSUD and UCD disorders 
calculated with respect to healthy control group.
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sodium phenylbutyrate, an ammonia scavenger known to produce a selective reduction in BCAAs39. We have 
found a significant inverse correlation between psychomotor delay and levels in plasma of BDNF and essential 
neutral AAs (mainly threonine, serine, phenylalanine, and BCAAs). These results highlight the necessity of care-
ful metabolic surveillance and diet formulation based on the changing energy requirements of growing patients, 
as excessive essential neutral amino acid restriction and low BDNF seems to be a hallmark of psychomotor delay.
Nevertheless, we cannot rule out a role for altered BDNF in MSUD neurocognitive and behavioral sequelae, as 
we have found statistically significant reductions in the expression of MECP2 mRNA, an epigenetic regulator of 
BDNF transcription40,41. In addition, we have found statistically significant reductions in CACNA2D2 mRNA in 
MSUD patients, which was inversely correlated with chronically elevated BCAAs levels. We also found increased 
levels of THBS1 in MSUD and UCD patients, which expression was unrelated to BCAAs levels but correlated 
positively with glutamine and negatively with BDNF plasma levels. Results that are in accordance with published 
reports showing TSP1 upregulation in mice brains with decreased levels of BDNF42. TSP1, the protein codified by 
THBS1, is an extracellular matrix (ECM) glycoprotein with antiangiogenic properties that exerts multifunctional 
effects by binding cell-surface receptors and other proteins in the ECM. TSP1 is up-regulated with injury, chronic 
pathologies and in response to glucose and AAs, being considered a potent modulator of human diseases43–45.
One of the most important findings of this work is the identification, at the level of mRNA and protein, of a 
biomarker signature specific at for MSUD that includes α2δ2 (AUC 0.865/0.925) and MeCP2 (AUC 0.942/0.857), 
as the combination of both yielded the excellent biomarker accuracy (AUC 1/0.95). No specific biomarker signa-
ture was found for UCD.
VGCCs auxiliary subunits α2δ1-2, codified by CACNA2D1-2 genes, regulate calcium ion entry in response to 
electrical activity in excitable cells46,47. In neurons, α2δ1-2 expression modulates neurotransmitter release prob-
ability, trafficking and gating properties of AMPA-selective glutamate receptors (AMPARs)48,49, and have been 
involved in learning, memory, anxiety-related behaviors and epilepsy in rats and humans50–54. α2δ1-2 subunits are 
also essential for the formation and stabilization of new synapses by binding to TSP1-4 secreted by astrocytes29,55. 
It is assumed that BCAAs can induce conformational changes that indirectly affect TSPs binding to α2δ1-2 [29, 
30, 31]. Moreover, α2δ subunits are the main targets of gabapentinoid drugs (gabapentin and pregabalin), which 
compete for the same binding site than BCAAs, blocking α2δ synaptogenic functions29, and biochemically mim-
icking the action of BCAAs56.
MeCP2 is an epigenetic regulator that preferentially binds to methylated CpG sites in promoter regions of 
DNA and is crucial for the correct brain development and the stability control of the neural network in response 
Figure 3. Correlation graphs and ROC curves for candidate biomarkers of neural dysfunction in IEM patients. 
(a) Graphs showing changes in BDNF and threonine in plasma of patients with deficits in psychomotor 
development and the ROC curves for different biomarker combinations calculated comparing affected 
with non-affected IEM patients. (b) ROC curves for THBS3 mRNA in blood and AABA in plasma and its 
combination for the detection of deficits in attention and/or executive functions calculated comparing affected 
with non-affected IEM patients. (c) Graphs showing changes in LIN28A mRNA in blood and alanine and 
cysteine in plasma of patients with other behavioral symptoms and the ROC curves for LIN28A. THBS3 and 
alanine biomarker combinations calculated comparing affected with non-affected IEM patients.
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to activity57–59. Excessive or defective MECP2 function causes neurodevelopmental disorders associated with 
mental retardation, epilepsy, loss of speech and anxiety, among others60–65.
In addition to the above described, glycine and taurine were significantly increased in MSUD patients, data 
that is coincidental with previous studies23,35, and they stand out for its very good MSUD biomarker performance 
(AUC glycine 0.909 and AUC taurine 0.889). Glycine and taurine are abundant in brain, where they are involved 
in several aspects of normal development including neurogenesis, neuronal migration and differentiation66,67. 
Both AAs act as neurotransmitters by binding to glycine receptors, to NMDA receptors (glycine) and to GABA 
receptors (taurine). In addition, taurine inhibits K+-Cl− cotransporter KCC2, modulating Cl− homeostasis, the 
functionality of inhibitory neurotransmission and neuronal excitability68,69. Thus, the increase in glycine and 
taurine together with the reduced levels of α2δ2 and MeCP2 observed in MSUD patients might reflect an altered 
synaptogenesis and misbalanced excitatory-inhibitory neural network.
Unexpectedly, although no significant differences were found, THBS3 mRNA together with AABA in plasma 
has revealed a good biomarker performance for executive function, attention deficits (AUC 0,911). Reduced 
AABA in plasma is a frequent consequence of low protein diets and it has been recently associated with depres-
sion in older Japanese patients70. TSP3 is developmentally regulated44 and few is known about functions. It has 
been involved in modulating integrin membrane expression and function71, which is also essential for the forma-
tion of correct synaptic structures72. As TSP3 is a secreted protein, ELISA analysis in plasma would be required to 
gain insight into their potential biomarker significance.
Finally, increased levels of LIN28A mRNA, alanine, and cysteine correlated with behavioral dysfunctions, 
which include autism spectrum disorder, depression or aggressiveness, and the combination of THBS3 with 
LIN28A and alanine gave a perfect biomarker signature (AUC 1). LIN28 RNA binding proteins inhibit the bio-
genesis of let-7 family of miRNAs, a group of miRNAs crucial for embryonic and postnatal development, being 
at least the 50% of miRNAs present in mature neurons73,74. LIN28/let-7 pathway has been involved in controlling 
cell growth and energy metabolism26, and regulate dendritic growth and cell survival in response to BDNF75. 
Elevated levels of LIN28 and disruption of let-7 biogenesis have been described in animal models and in blood of 
patients with major depression76,77. Previous studies described that elevated levels of cysteine in infants derived 
in behavioral deficits in adults78 and plasma levels of alanine have been proposed as a marker of depression 
severity79. Taking together, our results are in concordance of what is observed in depression, which is commonly 
described in patients with inborn errors of metabolism, including UCD and MSUD80,81.
Our study, though preliminary, has identified several potential biomarker panels for neural function evalua-
tion, providing a base for future studies. Most importantly, α2δ2 and MeCP2 showed an excellent neural function 
biomarker signature for MSUD. In addition, THBS3 mRNA and AABA gave a very good biomarker signature for 
executive and attention deficits. THBS3 and LIN28A mRNA and alanine showed a perfect biomarker signature 
for behavioral and mood disorders. Finally, a panel of BDNF and large neutral AAs showed a perfect biomarker 
Biomarker Panel
Psychomotor Delay Executive/Attention Deficits Other Behavioral Symptoms
AUC Desv error p value Trend AUC Desv error p value Trend AUC Desv error p value Trend
Leu 0.796 0.086 0.017 ↓ 0.753 0.098 0.035 ↓
Ile 0.803 0.085 0.015 ↓
Ala 0.793 0.101 0.023 ↑
Ser 0.757 0.110 0.038 ↓
Thr 0.776 0.104 0.026 ↓
Cys 0.779 0.098 0.031 ↑
Phe 0.763 0.116 0.034 ↓
Lys 0.743 0.019 0.049 ↓
Cit 0.809 0.110 0.013 ↑ 0.754 0.137 0.050 ↑
AABA 0.743 0.113 0.049 ↓ 0.777 0.096 0.021 ↓
LIN28A 0.771 0.101 0.045 ↑
MECP2 E1 0.780 0.125 0.043 ↑
MECP2 E2 0.733 0.127 0.084 ↑ 0.762 0.124 0.053 ↑
THBS3 0.857 0.091 0.034 ↑ 0.791 0.127 0.036 ↑
BDNF 0.792 0.120 0.039 ↓
BDNF + Ser 0.964 0.041 0.001
BDNF + Thr 0.940 0.062 0.002
BDNF + MECP2 E1 0.909 0.080 0.007
BDNF + (Thr/Ser/
Phe) + (Ile/Leu) 1.000 >0.000 0.001
BDNF + (Thr/Ser) + Cit 1.000 >0.000 0.001
THBS3 + AABA 0.911 0.073 0.015
LIN28A + THBS3 0.870 0.085 0.010
LIN28A + THBS3 + Ala 1.000 >0.000 >0.000
Table 6. Area under the curves (AUC) of the biomarker combinations for neuropsychiatric function in IEM 
patients calculated comparing affected with non-affected patients.
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signature for psychomotor delay, pointing to excessive protein restriction as potential causatives of psychomotor 
delay in diet-treated IEM patients. Although these results are very promising, a large number of clinical samples 
should be collected and the potential biomarkers in each panel quantified at the protein level for the ultimate goal 
to translate these neural function biomarkers to the clinical practice.
Material and Methods
ethical statement. Research Ethics Committee of both hospitals, Sant Joan de Déu and Santiago de 
Compostela Hospitals, approved the study and informed consent was subscribed by patients and controls (when 
>18 years old) or by their parents (when <18 years old) prior to the collection of data. All methods were per-
formed in accordance with the relevant guidelines and regulations.
subjects and assessment. 19 patients with a diagnosis of UCDs, 9 patients diagnosed with MSUD, 1 
patient with BCKDK (branched-chain ketoacid dehydrogenase kinase deficiency) and 27 healthy age-matched 
control subjects were recruited for the study at Sant Joan de Déu Hospital in Barcelona and University Hospital 
of Santiago de Compostela, Spain. Patients were followed in their respective center with the same standardized 
protocol (Haeberle et al. 2012) from the date of diagnosis up to current date. Controls were healthy age-matched 
individuals with no history of learning difficulties, psychiatric and behavioral problems, who underwent blood 
analysis in the context of minor surgical interventions.
Inclusion criteria were patients with genetic and/or enzymatic diagnosis of UCDs, MSUD, and BCKDK; 
asymptomatic and female carriers of OTC deficiency were also included because of abnormal metabolic pro-
file that required a protein-restricted diet. Table 1 summarizes the clinical characteristics of the patients. We 
evaluated the following parameters: age of symptoms onset, psychomotor development and number of decom-
pensations (defined as symptomatic hyperammonemia episode with plasma ammonia greater than 100 μmol/L 
or amino acid decompensation with leucine greater than 1000 µmol/L). Cognitive functions were assessed by 
Wechsler Intelligence Scale for Children (WISC)-IV or Kaufman Brief Intelligence Test, Second Edition (K-BIT), 
considering five severity levels for intellectual disability: Borderline = IQ 70–85, Mild = IQ 55–70; Moderate = IQ 
40–55; Severe IQ 25–40; Profound IQ < 25. Behavioral disorders, attention, and executive functions were assessed 
by NEPSY-II subtests, Behavior Rating Inventory for Executive Functions (BRIEF) and Conners’ Continuous 
Performance Test II (CPT II). ADHD rating scale –IV (Dupaul) was used for behavioral characterization associ-
ated with attention-deficit hyperactivity disorder.
peripheral blood sample collection. Venous blood samples were collected in an anticoagulation EDTA 
tube after overnight fasting. Biochemical measurements of plasma ammonia, and amino acids were assessed by 
spectrophotometric technique and ion-exchange chromatography respectively.
Gene expression assays. RNA from 500 µL of whole blood was extracted using miRCURY™ RNA 
Isolation Kit - Cell & Plant (300110 Exiqon) following supplier instructions. RNA concentration and purity were 
analyzed in IMPLEN NanoPhotometer® P-Class (Implen). RNA samples (0.5–1 µg) were reverse transcribed 
to cDNA (High Capacity cDNA Reverse Transcription Kit, 4368814, Applied Biosystems) and Real-Time PCR 
was performed using TaqMan PCR Assays (4331182, Applied Biosystems) with TaqMan Universal PCR Master 
Mix (4324018, Applied Biosystems) in the 7900HT Real-Time PCR System (Applied Biosystems). Assays ana-
lyzed were: ADORA2A (Hs00169123_m1), CACNA2D2 (Hs01021049_m1), FMR1 (Hs00924547_m1), IRAK1 
(Hs01018347_m1), LIN28A (Hs00702808_s1), PTEN (Hs02621230_s1), MECP2 E1 (Hs01598237_m1), MECP2 
E2 (Hs00172845_m1), THBS1 (Hs00962908_m1), THBS3 (Hs00938498_m1). GUSB (Hs00939627_m1) and 
GAPDH (Hs99999905_m1) were used as endogenous controls. Data analysis was performed with Expression 
Suite Software (Life Technologies) and data expressed as Relative Quantification (RQ) normalized with respect to 
gusb. Sample exclusion criteria were: threshold cycles (Cts) of more than 35, replicates with a standard deviation 
greater than 0.25 and Cts of GAPDH and GUSB not consistent. Outliers (identified using interquartile ranges) 
were removed from the analysis.
BDNF protein detection. The remaining whole blood was centrifuged at 2000 rpm 10 minutes and the 
plasma obtained was frozen at −80 °C until use. BDNF was measured in duplicates using RayBio® Human BDNF 
ELISA Kit following supplier instructions.
Western Blot analysis. Leukocytes were obtained from pelleted blood cells after red blood cells lysis with 
RBC Lysis Buffer (21205, Norgen Biotek corp) following supplier instructions. Proteins were extracted, sepa-
rated by SDS-page in polyacrylamide gels, and transferred to nitrocellulose membranes (1620112, Bio-Rad). 
Membranes were blocked for 1 hour at room temperature, primary antibodies were incubated overnight at 4 °C 
and then with their corresponding secondary HRP-conjugated antibodies for 1 hour (1:5000, Invitrogen). Protein 
signal was detected with ECL chemiluminiscent system (Amersham, GE Healthcare) in ImageQuant LAS 500 
(GE Healthcare). Images were processed with Image Studio Lite 5.2 (LI-COR). Densitometry analysis was per-
formed using gapdh as loading control and ImageJ software (National Institutes of Health). Primary antibodies: 
rabbit anti- α2δ2 (1:500, Abgent, AP13380C), rabbit anti-MeCP2 (1:1500, Millipore, ABE333), rabbit anti-TSP3 
(1:1000, Abgent, AP18972a), rabbit anti-LIN28A (1:200, #8641, Cell Signaling) and mouse anti-Vinculin (1:750, 
SCBT, sc-59803). Full length gels are shown in Supplementary info file.
Data analysis. SPSS program (IBM SPSS Statistics 24.0) was used to analyze data.
Two tailored non-parametric Kruskal Wallis and Mann-Whitney U tests were used to establish metabolic 
and gene expression differences between conditions and to correlate candidate biomarkers with clinical variables 
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respectively, as the sample size was not enough to presume normality within the data. Signification values in 
multiple comparisons were adjusted by Bonferroni correction to reduce Type 1 Error. A bivariate correlation test 
was used to correlate quantitative variables while Pearson product-moment correlation was used if both variables 
were qualitative.
To assess biomarker feasibility Receiver Operating Characteristic (ROC) curves and the area under the 
ROC curve (AUC) were performed. AUC vary from 0 to 1, where values 0.8 ≤ AUC < 0.9 reflect good and 
0.9 ≤ AUC ≤ 1 very good biomarker performance. Statistical significance was set at p values *p < 0.05, **p < 0.01 
and ***p < 0.001.
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